Form 4: AN2 Therapeutics Executive Sells Shares

AN2 Therapeutics COO and Chief Legal Officer Joshua M. Eizen reported a sale of 5,945 shares of common stock on July 8, 2026, to cover tax withholding obligations.

Summary

• Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc., reported a transaction on July 8, 2026.
• The transaction involved the sale of 5,945 shares of common stock at a price of $4.172 per share.
• This sale was made to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on July 1, 2026.
• Following this transaction, Eizen beneficially owns 206,554 shares of common stock.
• This ownership includes various RSUs with different vesting schedules and 5,000 shares purchased under the company's Employee Stock Purchase Plan on March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider selling shares, the reason is clearly stated as tax withholding, a common and expected event for equity compensation.

Positives

• The sale was conducted to cover tax obligations, indicating a standard procedure for equity compensation rather than a distress sale.
• Eizen continues to hold a significant number of shares (206,554) after the transaction, suggesting ongoing commitment to the company.
• The filing details a diversified RSU portfolio with staggered vesting, which can provide ongoing incentives and retention for the executive.

Negatives

• A portion of the executive's equity was sold, which could be perceived negatively by the market if not clearly explained as a tax-related event.

Risks

• The vesting of RSUs and subsequent tax withholding obligations are a recurring event that may lead to further share sales by management.
• The overall market perception of insider selling, even for tax purposes, can sometimes negatively impact stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Management Comments

• The sale of shares was made pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ('RSUs') on July 1, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and are common across the biotechnology and pharmaceutical sectors as companies utilize equity-based compensation. The sale described is a standard mechanism for executives to manage tax liabilities associated with vested equity awards.

Stakeholder Impact

• Shareholders: The sale is for tax purposes and does not necessarily indicate a negative view of the company's prospects, but any insider selling can create short-term market perception issues.
• Employees: The RSU structure and vesting schedules are part of the company's employee compensation strategy.
• Management: The transaction is a standard part of executive compensation and tax management.

Next Steps

• Continued monitoring of future Form 4 filings for any additional transactions by Joshua M. Eizen or other AN2 Therapeutics executives.
• Tracking the vesting schedules of the remaining RSUs to anticipate potential future tax-related sales.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership, Executive Compensation